Express Next Day Delivery

Switching from Wegovy to Mounjaro: What You Need to Know

If you're currently taking Wegovy and considering a switch to Mounjaro, it's essential to understand the differences between these medications and how the transition may affect your weight loss journey. Whether you're experiencing side effects with Wegovy or seeking more effective treatment, exploring your options is crucial for your health and well-being.


Understanding the Difference

Wegovy and Mounjaro both target obesity, but they contain distinct active ingredients. Wegovy contains semaglutide, while Mounjaro contains tirzepatide. These differences can influence how your body responds to the medication and its effectiveness in aiding weight loss.

In the realm of diabetes management and weight loss, medications like Mounjaro and Wegovy are making waves. Both belonging to the class of GLP-1 receptor agonists, they operate by mimicking the hormone GLP-1 to facilitate weight loss and regulate blood sugar levels.

However, Mounjaro offers a unique twist in its approach. In addition to mimicking GLP-1, it also mirrors GIP, another hormone known for its appetite-suppressing properties. This dual function sets Mounjaro apart, effectively tackling hunger while aiding in weight loss and blood sugar control.

Manufactured respectively by Eli Lilly and Novo Nordisk, Mounjaro contains tirzepatide as its active ingredient, while Wegovy is semaglutide. Despite sharing a similar mechanism of action, data from randomized controlled trials indicate that Mounjaro tends to outshine Wegovy in terms of weight loss efficacy.


How do they work 

When food is consumed, hormones are released by the gut to aid in hunger and blood sugar regulation. Among these hormones is GLP-1, also known as glucagon-like peptide-1.

GLP-1 enhances insulin activity, thereby reducing blood sugar levels and slowing down gastric emptying, which in turn reduces appetite.

Furthermore, GLP-1 interacts with the hypothalamus, the brain's center for appetite regulation, to diminish food-seeking behavior.

Additionally, Mounjaro mimics the hormone GIP, which bears resemblance to GLP-1.

GIP is released post-food consumption to aid in blood sugar regulation and enhance the absorption of excess energy by fat cells, thereby preventing fat accumulation in the liver or pancreas.

Similar to GLP-1, GIP also interacts with receptors in the brain, leading scientists to hypothesize its involvement in appetite regulation.


Reasons to Consider a Switch

There are several reasons why you might contemplate switching from Wegovy to Mounjaro. If you're not seeing significant weight loss despite being on the highest dose of Wegovy, or if you're experiencing intolerable side effects, Mounjaro could be a viable alternative. Each person's response to weight loss medication varies, so finding the right fit for your body is essential.


Comparing Effectiveness

Clinical trials have suggested that both medications are effective for chronic weight management, but Mounjaro may offer slightly better results than Wegovy. Studies have shown that Mounjaro leads to greater weight loss compared to Wegovy, highlighting its potential as a more effective treatment option.

After a 40-week period, Mounjaro demonstrated greater weight loss compared to Ozempic. Findings revealed that the higher dosage (15 mg) of Mounjaro resulted in nearly double the weight loss compared to a 1 mg dose of Wegovy/Ozempic.

In a randomized controlled trial involving 1,897 individuals with type 2 diabetes, the effects of three doses of tirzepatide (5 mg, 10 mg, and 15 mg) were compared to a weekly injection of 1 mg semaglutide (Ozempic) concerning blood sugar levels.

The results indicated that all three tirzepatide doses led to more substantial weight loss than the 1 mg dose of semaglutide.


Understanding Dosing

Wegovy and Mounjaro have different dosing regimens. Wegovy comes in five strengths, to be taken weekly, with doses increasing gradually until reaching a maintenance dose determined by you and your prescriber. Mounjaro, on the other hand, comes in six strengths, also taken weekly, with doses adjusted based on your response to the medication.

However side effects and effectiveness vary from person to person as we all respond differently to the same medications. 

In a randomised controlled trial with over 1,800 participants comparing tirzepatide to semaglutide, the tirzepatide group reported more serious adverse events (5-7% VS 3%) and higher discontinuation rates due to adverse events (6-8.5% VS 4%). 


Making the Switch

Before transitioning from Wegovy to Mounjaro, it's crucial to consult your prescriber. They can assess your individual needs and ensure a smooth transition between medications. Restarting with Mounjaro will require starting from the lowest dose and gradually increasing it, similar to the titration process with Wegovy. Following your prescriber's guidance is essential to minimize the risk of side effects and maximize the benefits of your new treatment.



Switching from Wegovy to Mounjaro can be done. By understanding the differences between these medications and their potential impact on your weight loss journey, you can make an informed decision that supports your health and well-being. Remember, effective weight management involves more than just medication – it requires a holistic approach that includes a balanced diet, regular exercise, and ongoing medical supervision.

Latest Stories

View all

Navigating GLP-1 Medications: Ultimate Guide for the community

Navigating GLP-1 Medications: Ultimate Guide for the community

Dr Sohaib Imtiaz our Clinical Lead and Board certified Lifestyle Medicine Doctor went live with our community. Here are some of the questions we were asked.  As the landscape of weight management medications evolves, questions arise about specific drugs, their...

Read more

Shareholders' letter | Year end 2021 updates - Rightangled

Shareholders' letter | Year end 2021 updates

The copy of an email newsletter sent by CEO Abdullah Sabyah to Rightangled investors on Christmas day (25th of December 2021), the letter covers a full overview and updates from the year-end 2021 with a business outlook to the year 2022.

Read more

Rightangled: Changing the Way We Look at DNA

Rightangled: Changing the Way We Look at DNA

According to the World Health Organisation, cardiovascular diseases (CVD) are the leading cause of deaths worldwide. An estimated 17.7 million people died from CVDs in 2015, representing 31% of all global deaths. In the UK alone, 7 million people battle with CVDs every day. Rightangled...

Read more